A novel approach to target inflammatory diseases

Using its proprietary technology platform, Inotrem is leveraging its extensive knowledge of the TREM-1 pathway biology to develop programs in several indications with inflammatory syndromes for which there is a major and today unsatisfied therapeutic need.

Nangibotide (LR12):

• Septic shock
Expanded Access Policy

• Acute myocardial infarction


Chronic inflammatory diseases


Nangibotide is a chemically synthetized peptide and a specific TREM-1 inhibitor. Among other features, nangibotide modulation restores a balanced inflammatory response (immunomodulation) and improves survival (shock reversal).

Inotrem’s lead product candidate, nangibotide (LR12) has been granted access to the EMA’s PRIority MEdicines (PRIME) scheme.